Psyched Wellness Ltd. develops and distributes health and wellness products derived from the Amanita Muscaria mushroom. Company news centers on its consumer supplement portfolio, including Calm, Calmer, AME-1 extract and related dietary supplement formats, along with product formulation, shelf-life, safety-study and flavor-profile updates.
Recurring developments also include retail and wholesale distribution relationships in Canada and the United States, manufacturing and supply-chain matters, regulatory and policy commentary affecting botanical wellness products, and board or executive governance changes. The company’s updates often connect product commercialization with route-to-market partnerships and the regulatory risks associated with Amanita Muscaria-derived consumer products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) is set to present at the KCSA Psychedelics Investor Conference on October 14 at 11:00am E.T. Jeffrey Stevens, CEO, will discuss the company's focus on artisanal functional and psychedelic mushrooms. Psyched aims to lead in the North American market with its Amanita muscaria-derived products targeting stress relief, relaxation, and restful sleep. Interested parties can register for the conference here.